04:23 PM EDT, 04/24/2024 (MT Newswires) -- BioMarin Pharmaceutical ( BMRN ) reported Q1 non-GAAP earnings late Wednesday of $0.71 per diluted share, up from $0.60 a year earlier.

Analysts polled by Capital IQ expected $0.60.

Revenue for the quarter ended March 31 was $648.8 million, up from $596.4 million a year earlier.

Analysts surveyed by Capital IQ expected $651.8 million.

The company now expects full year 2024 non-GAAP diluted EPS between $2.75 and $2.95, compared with the previous guidance of between $2.60 and $2.80. It still expects full year 2024 revenue between $2.7 billion and $2.8 billion.

Analysts polled by Capital IQ expect normalized EPS of $2.75 and revenue of $2.76 billion.

Shares were down more than 3% in after-hours activity.

Price: 88.02, Change: -3.18, Percent Change: -3.49